ArticleGastroenterology report2025
Incidence trends and disparities in infection-related malignancies of the liver among US adults, 2000-2019.
Article in Gastroenterology report, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From organelles to therapy: rethinking combined hepatocellular-cholangiocarcinoma.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Trend analysis in infection-related malignancy of the liver is still limited. We aimed to evaluate the incidence trend in hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), combined hepatocellular carcinoma and cholangiocarcinoma (cHCC-CCA), and primary hepatic lymphoma (PHL) in the USA during 2000-2019. Method: In this population-level study, cases of HCC, iCCA, cHCC-CCA, and PHL from the Surveillance, Epidemiology, and End Results (SEER) registries during 2000-2019 were included. The average annual percentage change (AAPC) in 2000-2019 was computed to describe the age-adjusted incidence trends for each disease and was stratified by demographic and geographic variables. Results: HCC and iCCA incidence increased from 5.51 (per 100,000 persons) to 8.83 and 0.92 to 1.94 during 2000-2019, respectively, whereas cHCC-CCA and PHL incidence plateaued at ∼0.04 and ∼0.10, respectively. The AAPCs of HCC, iCCA, cHCC-CCA, and PHL were 2.5% (95% confidence interval [CI], 2.2% to 2.8%), 3.9% (95% CI, 2.1% to 5.7%), 0.4% (95% CI, -1.1% to 1.9%), and 0.2% (95% CI, -0.9% to 1.3%), respectively. The HCC incidence patterns differed between age groups, with a decreased trend for young adults (AAPC, -1.1% [95% CI, -2.2% to -0.1%]) and the fastest increase trend for elderly people (AAPC, 3.2% [95% CI, 2.8%-3.5%]). For iCCA, the incidence significantly increased for all age and race/ethnicity subgroups. The incidence trends in cHCC-CCA and PHL plateaued for the general population and all subgroups. Geographic disparities were found for HCC, with the highest proportion in Alaska Natives (91.6%) and the lowest proportion in Iowa (77.5%). Conclusions: Although the incidence of infection-related malignancies of the liver increased in the USA during 2000-2019, a plateaued trend was observed for HCC during 2010-2019, especially for young adults. Racial/ethnic differences and geographic diversity remain. Systematic screening and prevention are highly requested.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.